Suma Krishnan
About
Suma Krishnan is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Cell Biology.
According to data from OpenAlex, Suma Krishnan has authored 29 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 7 papers in Cellular and Molecular Neuroscience and 7 papers in Cell Biology. Recurrent topics in Suma Krishnan's work include Attention Deficit Hyperactivity Disorder (14 papers), Bipolar Disorder and Treatment (8 papers) and Skin and Cellular Biology Research (7 papers). Suma Krishnan is often cited by papers focused on Attention Deficit Hyperactivity Disorder (14 papers), Bipolar Disorder and Treatment (8 papers) and Skin and Cellular Biology Research (7 papers). Suma Krishnan collaborates with scholars based in United States, Chile and Austria. Suma Krishnan's co-authors include Joseph Biederman, Jeffrey G. Stark, Robert L. Findling, James J. McGough, Yuxin Zhang, Ann Childress, Samuel W. Boellner, Yuxin Zhang, Frank A. López and Yuxin Zhang and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Suma Krishnan
27 papers receiving 1.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Suma Krishnan United States | 17 | 987 | 377 | 365 | 187 | 165 | 29 | 1.5k | ||
| Klaus‐Henning Krause Germany | 16 | 462 0.5× | 235 0.6× | 251 0.7× | 42 0.2× | 160 1.0× | 51 | 952 | ||
| K. L. Reichelt Norway | 22 | 525 0.5× | 249 0.7× | 542 1.5× | 113 0.6× | 414 2.5× | 57 | 1.4k | ||
| Iris E. Martínez‐Juárez Mexico | 19 | 607 0.6× | 252 0.7× | 163 0.4× | 40 0.2× | 139 0.8× | 60 | 1000 | ||
| Xintong Wu China | 18 | 372 0.4× | 120 0.3× | 284 0.8× | 14 0.1× | 92 0.6× | 80 | 951 | ||
| Nicola Pietrafusa Italy | 17 | 380 0.4× | 145 0.4× | 75 0.2× | 15 0.1× | 159 1.0× | 43 | 770 | ||
| Qinrui Li China | 12 | 197 0.2× | 49 0.1× | 229 0.6× | 55 0.3× | 359 2.2× | 22 | 746 | ||
| Eszter Molnár Hungary | 21 | 77 0.1× | 209 0.6× | 130 0.4× | 165 0.9× | 356 2.2× | 79 | 1.2k | ||
| Ronald E. Saul United States | 13 | 300 0.3× | 35 0.1× | 202 0.6× | 61 0.3× | 80 0.5× | 22 | 688 | ||
| Keiko Endo Japan | 15 | 108 0.1× | 93 0.2× | 158 0.4× | 34 0.2× | 174 1.1× | 53 | 642 | ||
| J.P. Müh France | 20 | 186 0.2× | 38 0.1× | 405 1.1× | 52 0.3× | 227 1.4× | 48 | 899 |
Countries citing papers authored by Suma Krishnan
Since
Specialization
Citations
This map shows the geographic impact of Suma Krishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suma Krishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suma Krishnan more than expected).
Fields of papers citing papers by Suma Krishnan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Suma Krishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suma Krishnan. The network helps show where Suma Krishnan may publish in the future.
Co-authorship network of co-authors of Suma Krishnan
This figure shows the co-authorship network connecting the top 25 collaborators of Suma Krishnan. A scholar is included among the top collaborators of Suma Krishnan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suma Krishnan. Suma Krishnan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Marinkovich, M. Peter, Amy S. Paller, Shireen V. Guide, et al.. (2025). Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. American Journal of Clinical Dermatology. 26(4). 623–635.
2.
Chen, Hubert, et al.. (2024). Wound behavior in dystrophic epidermolysis bullosa: A retrospective natural history case series. Journal of the American Academy of Dermatology. 91(5). 941–943.
3.
Chen, Hubert, et al.. (2024). Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa. New England Journal of Medicine. 390(6). 530–535.
4.
Gurevich, Irina, Pooja Agarwal, Henry Liu, et al.. (2022). In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nature Medicine. 28(4). 780–788.
5.
Guide, Shireen V., Mercedes E. González, Işın Sinem Bağcı, et al.. (2022). Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. New England Journal of Medicine. 387(24). 2211–2219.
6.
Freedman, John C., Trevor J. Parry, Avijit Majumdar, et al.. (2020). Preclinical Evaluation of a Modified Herpes Simplex Virus Type 1 Vector Encoding Human TGM1 for the Treatment of Autosomal Recessive Congenital Ichthyosis. Journal of Investigative Dermatology. 141(4). 874–882.e6.
7.
Atanasova, Velina S., Pooja Agarwal, Suma Krishnan, et al.. (2019). Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts. Journal of Investigative Dermatology. 139(7). 1497–1505.e5.
8.
Lebel, François, John Barrett, E. Antonio Chiocca, et al.. (2016). Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.. Journal of Clinical Oncology. 34(15_suppl). 2052–2052.
9.
Boellner, Samuel W., Jeffrey G. Stark, Suma Krishnan, & Yuxin Zhang. (2010). Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study. Clinical Therapeutics. 32(2). 252–264.
10.
Krishnan, Suma, Michael Pennick, & Jeffrey G. Stark. (2008). Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate. Clinical Drug Investigation. 28(12). 745–755.
11.
Adler, Lenard A., D. Wayne Goodman, Scott H. Kollins, et al.. (2008). Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder. The Journal of Clinical Psychiatry. 69(9). 1364–1373.
12.
Findling, Robert L., Ann Childress, Suma Krishnan, & James J. McGough. (2008). Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder. CNS Spectrums. 13(7). 614–620.
13.
Krishnan, Suma, et al.. (2008). Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. Journal of Psychopharmacology. 23(4). 410–418.
14.
Krishnan, Suma & Yuxin Zhang. (2008). Relative Bioavailability of Lisdexamfetamine 70‐mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single‐Dose, Crossover Pharmacokinetic Study. The Journal of Clinical Pharmacology. 48(3). 293–302.
15.
Krishnan, Suma, et al.. (2007). Toxicity Profile of Lisdexamfetamine Dimesylate in Three Independent Rat Toxicology Studies. Basic & Clinical Pharmacology & Toxicology. 101(4). 231–240.
16.
Biederman, Joseph, Samuel W. Boellner, Ann Childress, et al.. (2007). Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study. Biological Psychiatry. 62(9). 970–976.
17.
Biederman, Joseph, Suma Krishnan, Yuxin Zhang, James J. McGough, & Robert L. Findling. (2007). Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clinical Therapeutics. 29(3). 450–463.
18.
Krishnan, Suma, et al.. (2006). An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes. Drug Metabolism and Disposition. 35(1). 180–184.
19.
Biederman, Joseph, et al.. (2006). Improvements in Symptoms of Attention-Deficit/Hyperactivity Disorder in School-Aged Children with Lisdexamfetamine Dimesylate [LDX; NRP104] and Mixed Amphetamine Salts Extended-Release vs. Placebo. Journal of Developmental & Behavioral Pediatrics. 27(5). 442–442.
20.
Ludovici, Donald, Michael J. Kukla, Suma Krishnan, et al.. (2001). Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU). Bioorganic & Medicinal Chemistry Letters. 11(17). 2225–2228.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Klaus‐Henning Krause Breakdown of academic impact, for papers by K. L. Reichelt Breakdown of academic impact, for papers by Iris E. Martínez‐Juárez Breakdown of academic impact, for papers by Xintong Wu Breakdown of academic impact, for papers by Nicola Pietrafusa Breakdown of academic impact, for papers by Qinrui Li Breakdown of academic impact, for papers by Eszter Molnár Breakdown of academic impact, for papers by Ronald E. Saul Breakdown of academic impact, for papers by Keiko Endo Breakdown of academic impact, for papers by J.P. Müh